Aryl hydrocarbon receptor (AhR) activation by 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) dose-dependently shifts the gut microbiome consistent with the progression of steatosis to steatohepatitis with fibrosis

Russell R. Fling^{1,3}, Tim R. Zacharewski^{2,3*}

¹ Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI 48824; flingrus@msu.edu

² Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI;

³ Institute for Integrative Toxicology, Michigan State University, East Lansing, MI 48824

* Correspondence: tzacher@msu.edu; Tel.: +1 (517) 355-1607

Abstract: Gut dysbiosis with disrupted enterohepatic bile acid metabolism is commonly associated with non-alcoholic fatty liver disease (NAFLD) and recapitulated in a NAFLD-phenotype elicited by 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) in mice. TCDD induces hepatic fat accumulation and increases levels of secondary bile acids including tauroolithocholic acid and deoxycholic acid, microbial modified bile acids involved in host bile acid regulation signaling pathways. To investigate the effects of TCDD on the gut microbiota, cecum contents of male C57BL/6 mice orally gavaged with sesame oil vehicle or 0.3, 3, or 30 µg/kg TCDD were examined using shotgun metagenomic sequencing. Taxonomic analysis identified dose-dependent increases in *Lactobacillus* species (i.e., *Lactobacillus reuteri*). Increased species were also associated with dose-dependent increases in bile salt hydrolase sequences, responsible for deconjugation reactions in secondary bile acid metabolism. Increased *L. reuteri* levels were further associated with mevalonate-dependent isopentenyl diphosphate (IPP) biosynthesis and menaquinone biosynthesis genes. Analysis of gut microbiomes from cirrhosis patients identified increased abundance of these pathways as identified in the mouse cecum metagenomic analysis. These results extend the association of lactobacilli with the AhR/intestinal axis in NAFLD progression and highlight the similarities between TCDD-elicited phenotypes in mice to human NAFLD.

Keywords: 2,3,7,8-tetrachlorodibenzo-*p*-dioxin; dioxin; aryl hydrocarbon receptor; non-alcoholic fatty liver disease; gut microbiome; fibrosis; gut dysbiosis; secondary bile acids

1. Introduction

Non-alcoholic fatty liver disease (NAFLD) is estimated to affect ~25% of the global population and is defined as a spectrum of progressive pathologies that include steatosis, immune cell infiltration/inflammation, fibrosis, and cirrhosis. It is associated with increased risk for hepatocellular carcinoma, and is the 2nd leading cause of liver transplants in the United States[1]. Other pathologies including obesity, type 2 diabetes (T2D), and coronary heart disease demonstrate high co-occurrence with NAFLD, e.g., ~40-70% in T2D patients and ~90% in obese patients[2]. A multi-hit hypothesis for NAFLD proposes several contributing factors to development and progression including disruptions in the immune system, adipose tissue metabolism, and the gut microbiome[3]. Emerging evidence also suggests environmental contaminants may play an underappreciated role in gut dysbiosis and NAFLD development[4–11]. Specifically, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD), a persistent environmental organochloride pollutant, induces steatosis and the progression to steatohepatitis with fibrosis in mice resembling human NAFLD development[9,12–14]. TCDD-induced dyslipidemia also

exhibits other similar NAFLD characteristics such as decreased VLDL secretion, free fatty acid accumulation, inhibition of β -oxidation, and disrupted cholesterol and bile acid metabolism[9,15–18].

The effects of TCDD and other related polychlorinated dibenzo-*p*-dioxins (PCDDs), dibenzofurans (PCDFs) and biphenyl (PCBs) as well as polyaromatic hydrocarbons (PAHs), are mediated through activation of the aryl hydrocarbon receptor (AhR), a basic helix-loop-helix/Per-Arnt-Sim transcription factor typically associated with xenobiotic metabolism[19]. In addition, the AhR plays an essential role in gut homeostasis through regulation of the immune system and bile acid metabolism[9,15,20,21], with endogenous and xenobiotic AhR ligands affecting the gut microbiome congruent with NAFLD-like pathology[8–10]. Moreover, gut dysbiosis is commonly reported in NAFLD, making the gut microbiome an attractive target for non-invasive diagnostic tools and potential target for intervention[22,23].

Although the AhR exhibits promiscuous binding activity for a wide variety of structurally diverse xenobiotics, natural products, and endogenous metabolites, its endogenous role remains unknown[24]. Upon ligand binding, the cytosolic AhR disassociates from chaperone proteins and translocates to the nucleus where it dimerizes with the AhR nuclear transporter (ARNT). The AhR/ARNT heterodimer complex then binds to dioxin response elements located throughout the genome, affecting gene expression[25]. Endobiotic ligands for the AhR include host-derived metabolites such as tryptophan catabolites (*e.g.*, L-kynurenine), microbial-produced indole derivatives (*e.g.*, indole-3-aldehyde produced by *Lactobacillus reuteri*), and compounds derived from fruits and cruciferous vegetables (*e.g.*, 6-formylindolo[3,2-*b*]carbazole [FICZ])[24]. Microbial produced indoles activate AhR in the intestine, affecting barrier function and homeostasis by regulating the intestinal immune system through CD4⁺ T-cell differentiation, and the induction of interleukin (IL)-22 and IL-10 cytokine production[25]. AhR-dependent IL-22 induction subsequently increases antimicrobial peptides expression in intestinal epithelial cells, inhibiting pathogen infection and inflammation[25–27].

Knockout models and/or treatment with endogenous and xenobiotic AhR ligands results in shifts in the gut microbiome with diverse effects depending on the model and ligand[8,11,27–29]. Shifts in Firmicutes/Bacteroidetes ratio can differ between AhR ligands, *e.g.*, 2,3,7,8-tetrachloro dibenzofuran decreased the ratio [8] whereas TCDD increased it[11]. However, responses in various AhR models are in agreement regarding increased secondary bile acids [8,9] and effects on segmented filamentous bacteria [8,11,28]. AhR knockout models, and treatment with TCDD or other endogenous compounds also demonstrate strong correlations between AhR activation and enrichment of *Lactobacillus* species, *i.e.*, *L. reuteri* [27–31]. Tryptophan catabolism to AhR ligands by *Lactobacillus* species is a proposed mechanism for gut microbial regulation of AhR signaling that modulates intestinal and gut microbiome homeostasis[27].

Bile acids also affect the gut microbiome by exerting antimicrobial activity[32]. Conversely, the gut microbiota play critical roles in host bile acid homeostasis through microbial metabolism that qualitatively and quantitatively impact bile acid composition with consequences for bile acid activated signaling pathways in the host. The gut microbiome performs the first step of bile acid deconjugation with subsequent oxidation, reduction or dehydroxylation reactions to produce diverse secondary bile acid molecular species[33]. Select secondary bile acids, *e.g.*, glycodeoxycholic acid [GDCA], demonstrate higher inhibition of bacterial growth compared to other primary and secondary bile acids[34]. In regards to the host, some secondary bile acids, *e.g.*, lithocholic acid [LCA] and deoxycholic acid [DCA]), exhibit high affinity for the farnesoid x receptor (FXR) and G protein-coupled bile acid receptor (TGR5, *a.k.a.*, GPBAR1), which regulate glucose, lipid, and bile acid homeostasis[35–37]. In human NAFLD, secondary bile acid metabolism is disrupted with bile acid analogs that target FXR and TGR5 signaling pathways under development for the treatment of liver disease [23,32,38].

Previous work has demonstrated serum levels of LCA and DCA increased following TCDD treatment suggesting enrichment for microbial bile acid metabolism[9]. To further explore dose-dependent disruptions in gut microbiome and microbial metabolism relevant to the progression of NAFLD-like pathologies, shotgun metagenomic analysis was used to examine the dose dependent taxonomic and metabolic disruptions elicited by TCDD.

2. Results

2.1. TCDD-elicited toxicity enriched for *Lactobacillus* species

Taxonomic analysis identified significant dose-dependent population shifts among caecum microbiota in response to TCDD. While no significance was observed between treatment groups at the phylum level, a decreasing trend was observed for Bacteroidetes concurrent with increasing trends in Firmicutes abundance (Figure 1a).

Figure 1. TCDD enriched *Lactobacillus* species in the cecum microbiota. Taxa abundance were assessed in metagenomic cecum samples from male C57BL/6 mice following oral gavage with sesame oil vehicle or 0.3, 3 or 30 µg/kg TCDD every 4 days for 28 days (n=3). Significant shifts in relative abundances of taxa are presented at the (A) phylum, (B) genus, (C) and species levels. Significance is denoted with an asterisk (*; adjusted p-value < 0.1).

At the genus level, *Turicibacter* was enriched by TCDD while the genus *Lactobacillus* trended towards enrichment (Figure 1b). Interestingly, at the species level, 10 out of 13 enriched species were from the *Lactobacillus* genus (e.g., *L. reuteri* and *Lactobacillus* sp. ASF360) as well as *Turicibacter sanguinis*. Conversely, the most abundant *Lactobacillus* species in vehicle treated mice, *Lactobacillus murinus*, trended towards a dose-dependent decrease (Figure 1c).

2.2 Bile salt hydrolase (*bsh*) levels correlated with significantly enriched species

Many *Lactobacillus* species deconjugate primary conjugated bile acids mediated by bile salt hydrolases (BSH), imparting bile acid tolerance[39]. To further investigate the effect of TCDD on bile acid metabolism, *bsh* sequences were annotated and quantified within metagenomic samples. Annotations to *bsh* were increased by TCDD and associated with enriched species including *L. reuteri* and *T. sanguinis* (Figure 1c, Figure 2a, and Table S1).

Figure 2. TCDD enriched *Lactobacillus* species possessing bile salt hydrolase (*bsh*). The presence of *bsh* gene sequences were assessed in metagenomic caecum samples from male C57BL/6 mice following oral gavage with sesame oil vehicle or 0.3, 3, or 30 $\mu\text{g/kg}$ TCDD every 4 days for 28 days using 3 independent cohorts ($n=3$). (A) The presence (green boxes) or absence of *bsh* sequences detected in any of the metagenomic samples ($n=3$) are denoted within the respective treatment

groups. Significant increases (*) or decreases (@) in normalized *bsh* abundances (adj. $p < 0.1$) are denoted. Also denoted is significantly increased species (#) determined by taxonomic analysis that corresponded with respective RefSeq species *bsh* annotations. Significance was determined by Maaslin2 R package. **(B)** Volcano plot displaying $\log_2(\text{fold-changes})$ in relative abundance of species between vehicle and 30 $\mu\text{g/kg}$ TCDD treatment groups versus $-\log(\text{adjusted } p\text{-values [adj. } p])$. Red dots denotes *bsh* sequences detected in 30 $\mu\text{g/kg}$ TCDD treatment group. Significance was determined by the DeSeq2 R package comparing only vehicle and 30 $\mu\text{g/kg}$ TCDD groups. Red dashed lines are reference to $-\log(0.05)$ value for y-axis and -1 and 1 for x-axis.

Conversely, *L. murinus* associated *bsh* annotations exhibited a dose-dependent decrease consistent with decreasing trends in taxonomic abundance. Although not reaching significance, many *bsh* sequences were also associated with unclassified Lachnospiraceae species including *Lachnospiraceae bacterium A4*, a community member reaching 5-23% relative abundance in the cecum metagenomic samples (Figure 2a). In contrast, *Lactobacillus gasseri* was enriched but no *bsh* sequences were identified (Figure 2b). To summarize, the top enriched species were also associated with increased abundances in *bsh* levels in the cecum.

2.3 TCDD enriched for mevalonate-dependent isoprenoid biosynthesis

To investigate other metabolic pathways imparting competitive advantages to TCDD-elicited gut environmental stresses, functional gene annotations associated with *L. reuteri*, the highest enriched species, were assessed. Among enriched uniref90 annotations in the cecum metagenomic dataset was the aromatic amino acid aminotransferase (UniRef90_A0A2S1ENB9) also classified to *L. reuteri* (Table S2). Aromatic amino acid aminotransferase produces a tryptophan metabolite, indole-3-aldehyde, a known AhR ligand reported to induce IL-22 *in vivo*[27]. Among 39 enzyme commission (EC) annotations that were enriched and associated with *L. reuteri* were several annotated to the isoprenoid biosynthesis pathway (Figure 3, Figure S1, and Table S3).

Figure 3. TCDD enriched genes from the mevalonate-dependent isoprenoid biosynthesis pathway. **(a)** Relative abundance of genes involved in isoprenoid biosynthesis and grouped by enzyme

commission (EC) numbers for the mevalonate dependent and 2-C-methyl-D-erythritol 4-phosphate (MEP) pathways in cecum samples from male C57BL6 mice following oral gavage with sesame oil vehicle or 0.3, 3, or 30 $\mu\text{g/kg}$ TCDD every 4 days for 28 days ($n=3$). Individual box plots are also numbered with the EC number matching the enzymatic step in pathway schematic. Adjusted p-values (adj. p) were determined by the Maaslin2 R package. Abbreviations.: 3-hydroxyl-3-methyl-glutaryl-CoA (HMG-CoA), (R)-5-Phosphomevalonate (mevalonate-5P), (R)-5-Diphosphomevalonate (mevalonate-5PP), 2-C-Methyl-D-erythritol 4-phosphate (MEP), 4-(Cytidine 5'-diphospho)-2-C-methyl-D-erythritol (CDP-ME), 4-(Cytidine 5'-diphospho)-2-C-methyl-D-erythritol (DEP-ME-2P), 2-C-Methyl-D-erythritol 2,4-cyclodiphosphate (MEcPP), 1-Hydroxy-2-methyl-2-butenyl 4-diphosphate (HMBPP).

Bacteria biosynthesize the isoprenoid, isopentenyl diphosphate (IPP), either through the mevalonate-dependent pathway, which is also found in mammals, or the methylerythritol phosphate (MEP)-pathway. Both *L. reuteri* and *Lactobacillus johnsonii* were the major contributors to mevalonate-dependent IPP biosynthesis pathway enrichment with almost all genes in the pathway increased by TCDD (Figure 3 and Figure S1). Gene enrichment in the alternative MEP-pathway were unchanged by TCDD. For *L. murinus*, only two EC annotations (EC 2.7.1.148, 4-Diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) kinase, and EC 5.3.3.2, isopentenyl-diphosphate Delta-isomerase) were identified in the MEP pathway also found in *L. reuteri* (Figure S2).

HUMAN3.0 analysis of a published metagenomics dataset of fecal samples from human cirrhotic patients (<https://www.ebi.ac.uk/ena/data/view/PRJEB6337>) [40] revealed strikingly similar results to our caecum samples from TCDD treated mice. Specifically, increased gene abundance associated with the mevalonate-dependent pathways was also evident in patients with compensated and decompensated liver disease (Figure 4).

Figure 4. Mevalonate-dependent isoprenoid biosynthesis genes are enriched in a published metagenomics dataset of fecal samples from cirrhosis patients. Humann3 analysis of fecal gut microbiomes in healthy (H, red, $n=52$), compensated (C, green, $n=48$), or decompensated (D, blue, $n=44$) cirrhosis for mevalonate-dependent and methyl-D-erythritol 4-phosphate (MEP) pathways.

Because bacterial cell wall restructuring has been reported in response to bile acids and different levels of isoprenoid biosynthesis pathways were identified, peptidoglycan biosynthesis was also assessed[44]. Most genes encoding enzymes required for peptidoglycan biosynthesis were present in the metagenomic dataset (Figure 6a) with no changes observed following TCDD treatment.

Figure 6. Peptidoglycan biosynthesis was unchanged by TCDD. **(A)** Relative abundance of peptidoglycan biosynthesis EC numbers identified in the metagenomic dataset. **(B)** Relative abundance of only *Lactobacillus* species classified to peptidoglycan biosynthesis EC numbers. Individual boxplots are numbered with the EC number matching the enzymatic step in pathway schematic. Adjusted p-values (adj.p) were determined by MAASLIN2. Abbreviations: UDP-N-acetyl-alpha-D-glucosamine (UDP-GlcNAc), UDP-N-acetylmuramate (UDP-MurNAc), UDP-N-acetyl-alpha-D-muramoyl-L-alanine (UDP-MurNAc-ALA), UDP-N-acetyl-alpha-D-muramoyl-L-alanyl-D-glutamate(UDP-MurNAc-Ala-D-Glu), UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-meso-2,6-diaminopimelate (UDP-MurNAc-Ala-D-Glu-m-DAP), D-Alanyl-D-alanine (D-Ala-D-Ala), UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-6-carboxy-L-lysyl-D-alanyl-D-alanine (UDP-MurNAc-ALA-D-Glu-m-DAP-D-Ala-D-Ala).

247 Undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-
 248 alanyl-D-alanine
 249 (Und-PP-MurNAc-Ala-D-Glu-m-DAP-D-Ala-D-Ala), Undecaprenyl-diphospho-N-acetylmuramoyl
 250 -(N-acetylglucosamine)-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine
 251 (Und-PP-MurNAc-GlcNAc-Ala-D-Glu-m-DAP-D-Ala-D-Ala)

252 However, serine-type D-Ala-D-Ala carboxypeptidase (Figure 6a, EC 3.4.16.4, step 14),
 253 responsible for peptidoglycan polymer crosslinking, trended upwards. Additionally,
 254 most peptidoglycan biosynthesis EC numbers had annotations to *L. reuteri* (Figure 6b).
 255 Overall, TCDD did not alter peptidoglycan synthesis related gene levels.

256 *De novo* menaquinone biosynthesis requires chorismate and the addition of a
 257 polyprenol diphosphate (*i.e.*, geranyl-geranyl diphosphate) (Figure 7a). Two alternative

Figure 7. TCDD-elicited effects on menaquinone biosynthesis. **(A)** Relative abundance of menaquinone biosynthesis EC annotations identified in the metagenomic dataset. Individual stacked bar plots are labeled with the EC number matching the enzymatic step in pathway schematic. Stacked bar plots of annotated EC numbers involved in menaquinone biosynthesis. Values are mean relative abundance (n=3) classified to respective species and in cecum samples from male C57BL/6 mice following oral gavage with sesame oil vehicle or 0.3, 3, or 30 µg/kg TCDD every 4 days for 28 days. **(B)** Menaquinone biosynthesis EC numbers classified to *Lactobacillus* species in the cecum metagenomic datasets. Adjusted p-values (adj. p) were determined by Maaslin2 R package.

pathways exist for menaquinone biosynthesis, the o-succinylbenzoate or futasoline route[45]. Only a few EC number annotations were detected for the futasoline pathway (EC 4.2.1.151 and EC 2.5.1.120), while all EC numbers were identified for the complete o-succinylbenzoate menaquinone pathway (Figure 7a). In the mouse cecum dataset, one

cies contributing to o-succinylbenzoate menaquinone biosynthesis pathway included *Escherichia coli*, several *Bacteroides* (e.g., *Bacteroides vulgatus* and *Bacteroides caecimuris*), and *Lactobacillus* species (e.g., *L. reuteri*) (Figure 7b and Table S6). No one species was annotated to the entire set of enzymes needed for *de novo* biosynthesis from chorismate, however *B. vulgatus* was annotated for 6 out of 9 genes in the pathway (Table S6). O-Succinylbenzoate synthase (Figure 6a, EC 4.2.1.113, step 4) was increased by 30 µg/kg TCDD with *L. reuteri* being the major contributor to relative abundance (Figure 7, step 4). *Lactobacillus* species annotated to menaquinone biosynthesis included *L. reuteri*, *L. murinus*, and *L. johnsonii*. Among annotated menaquinone biosynthesis EC numbers, *L. reuteri* was among the identified *Lactobacillus* species that had the highest relative abundance and most menaquinone EC annotations (Figure 7b). *L. reuteri* also had annotations in samples for EC numbers involved in the final steps of the shikimate pathway responsible for chorismate biosynthesis (Table S7).

In cirrhosis samples, several EC numbers representing the initial menaquinone biosynthesis steps were also increased in compensated and decompensated patients (Figure 8, steps 1,3,4-5) including o-succinylbenzoate synthase (Figure 8, EC 4.2.1.113, step 4).

Figure 8. Menaquinone biosynthesis genes are increased in cirrhotic patients. Humann3 analysis of fecal metagenomic dataset of patients with healthy (H, red, n=52), compensated (C, green, n=48), or decompensated (D, blue, n=44) liver cirrhosis diagnosis for EC numbers in menaquinone biosynthesis. Individual box plots are labeled with the EC number matching the enzymatic step in pathway schematic. Significance is denoted with a red asterisk (*; adjusted p-values < 0.05) with the healthy group as reference.

However, *L. reuteri* was not among species classified to this EC number. Species classified to all EC numbers comprising the complete pathway included *E. coli*, and *Klebsiella* species such as *K. pneumoniae* and *Citrobacter* species. *L. reuteri* was not annotated to any menaquinone biosynthesis genes in healthy or compensated patients, but several EC numbers in the decompensated group (EC 6.2.1.26, 4.1.3.6, and 2.1.1.163) which are involved in later stages of menaquinone biosynthesis (Table S8).

3. Discussion

Previous studies have reported that TCDD elicited NAFLD-like pathologies, dysregulated bile acid metabolism and gut microbiome dysbiosis [9,11,15,29,31]. This study further elucidated the shifts in the gut microbiota associated with TCDD treatment using shotgun metagenomic sequencing. We show TCDD dose-dependently shifted the gut microbiota composition by enriching for *Lactobacillus* species, consistent with hepatic disruption of host and microbial bile acid metabolism. In addition, TCDD enriched for genes involved in mevalonate dependent isoprenoid precursor biosynthesis and menaquinone biosynthesis, crucial for microbial cell growth and survival. Over-representation of these microbial associated pathways were also identified in human cirrhosis stool metagenomics datasets.

TCDD-elicited gut dysbiosis is in agreement with observed effects in published *in vivo* studies following treatment with endogenous (*i.e.*, FICZ) and exogenous (*i.e.*, TCDD and TCDF) AhR agonists[8,9,11,29–31]. More specifically, we observed an increased Firmicutes/Bacteroides ratio with dose-dependent increases in *Lactobacillus* species[29,31]. *Lactobacillus* species are often associated with NAFLD, with increased abundances in patients with diabetes and liver fibrosis[46]. Probiotic *Lactobacillus* species including *L. reuteri* supplementation is also reported to alleviate NAFLD pathologies by reducing steatosis[47], fibrosis[48], insulin resistance[49] and serum cholesterol levels[50]. However, *Lactobacillus* species supplementation may also exacerbate fibrosis[51]. In humans and mice, *L. reuteri* supplementation can modulate the gut microbiota and alter bile acid metabolism. *L. reuteri* enrichment also approached comparable levels compared to samples from humans and mice administered probiotic supplementation[52,53]. We observed a species-specific increase of *L. reuteri* with a concurrent decrease in *L. murinus* suggesting shifts in *Lactobacillus* composition at the species and/or strain levels. Further, decreased abundance of *L. murinus* has been reported in human NAFLD[54]. Other taxa enriched following treatment included *Turicibacter sanguinis*, an anaerobic gram-positive bacillus commonly found in animals, including humans[55]. Interestingly, *T. sanguinis* has been shown to deconjugate bile acids and metabolize serotonin affecting lipid and steroid metabolism[55,56]. Quantitative trait locus analysis correlated *T. sanguinis* abundance with cholic acid levels and expression of the intestinal bile acid transporter *Slc10a2*[55]. Both cholic acid levels and *Slc10a2* expression are dose-dependently increased by TCDD[9]. Consequently, the dose-dependent taxonomic shift in *Lactobacillus* and *Turicibacter* species known to deconjugate conjugated bile acids is consistent with increased levels of secondary bile acids following TCDD treatment.

Some host relevant intestinal health and homeostatic effects can be attributed to *Lactobacillus* species mediated by bile salt hydrolases (BSHs) which are responsible for deconjugation reactions, the gateway step for conversion of conjugated primary bile acid to secondary bile acids [57]. A majority of *Lactobacillus* species possess BSHs, often containing multiple different gene copies within their genome, some with different bile acid substrate preferences[34,39]. However, the presence of *bsh* sequences does not simply infer bile acid tolerance as growth inhibition and reduced fitness is also possible depending on the conjugated or deconjugated bile acids present and/or BSH specificity.[34,39,58] For example, *L. gasseri* *bsh* knockout mutants exhibit increased fitness compared to wild type strains[39]. Interestingly, *L. gasseri* *bsh* sequences were not identified despite increased *L. gasseri* abundance following TCDD treatment. Our *bsh* analysis also found TCDD enriched *Lactobacillus*-associated sequences that may impart bile acid tolerance. For example, the *bsh* sequence enriched by TCDD annotated to *L. johnsonii* (RefSeq ID: EGP12391) (Table S3) exhibited higher substrate specificity for glycine over taurine conjugated bile acids[59,60]. In a companion study using the dose response and treatment regimen, Fader *et al* reported TCDD increased serum DCA levels ~80-fold, with only a ~ 2-fold increase in serum GDCA levels[9]. In contrast, hepatic tauroolithocholic acid (TLCA) levels were increased ~233-fold while serum lithocholic acid increased only 4-fold following TCDD treatment. Moreover, glycine conjugated bile acids including

GDCA are more toxic towards *Lactobacillus* species than taurine conjugated bile acids[34,61,62]. Increased levels of BSH with a substrate preference for glycine conjugated bile acid may partially explain select *Lactobacillus* species enrichment. Further, both TLCA and DCA are potent FXR and GPBAR1 agonists that regulate lipid, glucose and bile acid metabolism[63,64]. Consequently, shifts in microbial secondary bile acids by *Lactobacillus* species may play a role in TCDD elicited gut dysbiosis impacting host regulation of energy homeostasis.

Coincident with increased levels of *bsh* was the dose-dependent increase in genes from the mevalonate-dependent isoprenoid biosynthesis, the pathway also used in mammals for cholesterol biosynthesis. The MEP pathway is the predominant isoprenoid biosynthesis pathway among gut microbiota while the mevalonate-dependent pathway is only found in select bacteria including *Lactobacillus* and *Streptococcus* species[65]. The output from either pathway is farnesyl diphosphate (FPP) and geranyl diphosphate (GPP), substrates required for polyprenol biosynthesis used in menaquinone and cell wall biosynthesis. Menaquinones are utilized by bacteria for anaerobic/aerobic respiration, providing antioxidant activity with menaquinone supplementation affecting the gut microbiome[66]. In the context of *L. reuteri*, we observed genes annotated to the shikimate pathway which is responsible for chorismate biosynthesis, a precursor for aromatic amino acids and the naphthoquinone head group of menaquinone, as well as genes involved in *de novo* menaquinone biosynthesis. While the complete biosynthesis pathway was not present in *L. reuteri*, it is consistent with other metagenomic reports of incomplete menaquinone biosynthesis pathways in gut *Lactobacillus* species [45]. It has been proposed that *Lactobacillus* species may participate in later menaquinone biosynthesis steps through the uptake of intermediates such as o-succinylbenzoate from other bacteria or dietary sources[45]. In addition, the ability to utilize menaquinones for respiration is typically not associated with *Lactobacillus* species. However, some lactic acid bacteria including *L. reuteri* strains demonstrate the ability to respire when menaquinone and heme are supplemented[67,68].

Metagenomic analysis also identified the mevalonate-dependent pathway enrichment in fecal samples from patients with cirrhosis. The mevalonate-dependent pathway is reported to be increased in fibrosis patients with autoimmune pathologies[69]. Isoprenoid biosynthesis pathways are also elevated in the lung microbiome of cystic fibrosis patients, with the MEP pathway enriched rather than the mevalonate route[70]. The association between fibrosis and isoprenoid biosynthesis enrichment warrants further investigation in the context of potential mechanisms contributing to bacterial fitness and/or fibrosis. Increased abundance of the mevalonate-dependent biosynthesis pathway could also be a biomarker of *Lactobacillus* and *Streptococcus* proliferation that is often associated with non-alcoholic steatohepatitis (NASH)/fibrosis[22,46]. We identified enrichment of the mevalonate-dependent pathway in both mouse and human microbiomes whereas the complete pathway was primarily annotated to *Streptococcus* and *Lactobacillus* species (Table S7). Other factors such simvastatin and proton pump inhibitors (PPI) that are commonly prescribed for NAFLD patients may also impact these microbial pathways. Simvastatin, which is primarily excreted in the feces[71], is reported to reduce bacterial growth by directly inhibiting bacterial HMG-CoA synthesis while PPIs inhibit *Streptococcus* species growth[72–74]. These microbiome-drug interactions highlight off target effects that should be considered when investigating novel NAFLD treatments such as new drug development and/or probiotic interventions.

In addition to increased mevalonate-dependent isoprenoid biosynthesis genes in cirrhotic patients, menaquinone biosynthesis gene abundance was also increased. This suggests taxa with the ability to produce menaquinone may have a competitive advantage when intestinal environmental conditions shift during disease progression. In cirrhosis patients, *E. coli* and *B. vulgatus* were associated with genes providing a majority of the menaquinone biosynthesis capacity. These species are also increased in human NAFLD[75]. Similar to the results in mice exposed to TCDD, *L. reuteri* was associated

with several menaquinone biosynthesis genes and only detected in decompensated cirrhosis patients but lacked the complete pathway (Table S10). In cirrhosis patients, it is unclear whether *L. reuteri* is participating in menaquinone metabolism and/or benefiting from increased abundance of species, like *E. coli* that are capable of producing menaquinones.

This study was designed to account for factors affecting gut microbiota analysis including coprophagia and circadian rhythm (refs). Significant shifts in taxa were observed in *Lactobacillus* species. However, the small group size (n=3) following adjustment for multiple testing lacked sufficient power to confirm more subtle shifts such as the 2-fold enrichment of *Lachnospiraceae* A4, an abundant community member associated with *bsh* sequences. Samples were also collected within the same Zeitgeber period to account for possible variations in relative microbiota levels due to circadian rhythm/diurnal regulation. In fact, *L. reuteri* is one gut microbiome member demonstrating changes in relative abundance in human samples due to circadian/diurnal regulation[76]. TCDD disrupted diurnal regulation of hepatic gene expression including bile acid biosynthesis genes which may contribute to *L. reuteri* enrichment[77].

Although the consequences of TCDD-elicited immune system effects on the gut microbiome were not assessed in this study, it is most likely a factor impacting *L. reuteri* enrichment. TCDD causes macrophage and dendritic cell migration out of the *lamina propria* with increased accumulation in the liver, possibly exacerbating hepatic inflammation and affecting intestinal immune responses[14]. The ability of *L. reuteri* to produce AhR ligands, upregulate IL-22, and associate with the mucosa and Peyer's patches provides geographical proximity for immune/microbiome crosstalk mediated by the AhR [27,78,79]. Besides immune cell regulation, TCDD increased bone formation and decreased bone marrow adiposity[80]. Interestingly, *L. reuteri* supplementation also increased bone density, but only when mice are induced towards an inflammatory state[81]. Overall, the dose-dependent increase in *L. reuteri* levels are consistent with increased bile acid levels, disruption of circadian/diurnal regulation and increased bone density[9,77,80,81].

In summary, *Lactobacillus* species were dose-dependently increased following AhR activation by TCDD, concurrent with the increase in *bsh* genes and increased primary and secondary bile acids. Specifically, *L. reuteri*, a keystone gut microbiome species is involved in microbial metabolism of bile acids and AhR ligands. The large and uniform enrichment of *L. reuteri* in this study also suggests environmental pressures such as increased levels of bile acids and antimicrobial peptides elicited by AhR activation may provide a complementary niche for *L. reuteri* that possess a gene repertoire not found in the closely related *L. murinus*. We also provide evidence on how *L. reuteri* metabolism could impact AhR, FXR and GPBAR1 signaling pathways, placing *L. reuteri* at the crossroads of bacterial/host interactions affecting glucose, bile acid, and immune regulation. Whether these microbial shifts in metabolism are adaptive and limit the intensity of adverse consequences or exacerbates steatosis to steatohepatitis with fibrosis progression warrants further investigation.

4. Materials and Methods

4.1 Animal treatment

Postnatal day 25 (PND25) male C57BL/6 mice weighing within 10% of each other were obtained from Charles River Laboratories (Kingston, NY) and housed and treated as previously described[9]. Briefly, mice were housed in Innovive Innocages (San Diego, CA) containing ALPHA-dri bedding (Shepherd Specialty Papers, Chicago, IL) in a 23°C environment with 30–40% humidity and a 12 hr/12 hr light/dark cycle. Aquavive water (Innovive) and Harlan Teklad 22/5 Rodent Diet 8940 (Madison, WI) were provided *ad libitum*. The rodent diet is a fixed formula complete diet with an energy density of 3.0 kcal/g and a nutrient ingredient composition including 22% protein, 5.5% fat, and 40.6%

carbohydrate. Mice (PND29) were orally gavaged at the beginning of the light cycle (between Zeitgeber time 0-3) with 0.1 ml sesame oil vehicle (Sigma-Aldrich, St. Louis, MO) or 0.3, 3 and 30 $\mu\text{g/kg}$ body weight TCDD (AccuStandard, New Haven, CT) every 4 days for 7 total exposures ($n=3$ per treatment group). The study was conducted in three cohorts with mice housed separately among treatment groups for a total of 9 mice per treatment group. In each cohort, three mice were housed per treatment group and one mouse was randomly selected from each treatment group per cohort ($n=3$ per treatment group for the metagenomic analysis) to account for coprophagia and ensure reproducibility. The first gavage was administered on day 0 of the study. On day 28, vehicle- and TCDD-treated mice (fasted for 6 hr with access to water) were weighed and euthanized between Zeitgeber time 0-3. Upon collection, cecums were immediately flash frozen in liquid nitrogen and stored at -80°C until analysis. All animal handling procedures were performed with the approval of the Michigan State University (MSU) Institutional Animal Care and Use Committee.

4.2 Metagenomic sequencing

Microbial DNA from cecum contents (~25 mg) was extracted using the FastDNA spin kit for soil (SKU 116560200, MP Biomedicals, Santa Ana, CA). Extracted DNA was submitted to Novogene (Sacramento, CA) for quality control, library preparation, and 150-bp paired-end sequencing at a depth 136-157 million reads using an Illumina NovaSeq 6000. Reads aligning to the C57BL/6 *Mus musculus* genome (NCBI genome assembly: GRCm38.p6) were identified, flagged, and removed using bowtie2[82], SamTools[83] and bedtools[84]. For human metagenomic analysis, reads were filtered against the human genome (NCBI genome assembly: GRCh37/hg19) using the Kneaddata bioinformatics tool developed at the Huttenhower Lab (<https://github.com/biobakery/kneaddata>).

4.3 Metagenomic taxonomic analysis

Kaiju was used for taxonomic analysis of mouse cecum metagenomic dataset. The reference database used was the progenomes database downloaded from the kaiju web-server (https://kaiju.binf.ku.dk/database/kaiju_db_progenomes_2020-05-25.tgz). Multivariate association between dose and taxonomy relative abundances used Maaslin2 (<https://github.com/biobakery/Maaslin2>)[85] with the following default settings used: normalization (total sum scaling), analysis method (general linear model), and Benjamini-Hochberg multiple test correction. Adjusted p -values for Maaslin2 analysis used dose (sesame oil vehicle (0), 0.3, 3, or 30 $\mu\text{g/kg}$ TCDD) as the fixed effect which was treated as continuous variable and the vehicle set for reference. For comparison of taxonomy between vehicle and 30 $\mu\text{g/kg}$ TCDD treatment groups, DeSeq2 was used to determine adjusted p -values using default settings[86].

4.4 Metagenomic functional analysis

The HUMAnN 3.0 bioinformatic pipeline[87] was used with default settings to classify reads to UniRef90 protein identifications using UniProt's UniRef90 protein data base (January, 2019). Reads aligned to UniRef90 identifications were mapped to enzyme commission (EC) number entries using the humann_regroup_table tool. Read abundance was normalized to gene copies per million reads (CPM) using the human_renorm_table tool. Multivariate association between dose and enzyme commission number relative abundance used Maaslin2 with same settings used for taxonomy analysis.

Xander (a gene-targeted assembler, https://github.com/rdpstaff/Xander_assembler) was used to annotate and quantify bile salt hydrolase sequences with the following settings: k-mer size=45, filter size=35, minimum assembled contig bit score=50, and minimum assembled protein contigs=100 [88]. Reference DNA and protein *bsh* sequences used for Xander were downloaded from

FunGenes Gene Repository and are listed in supplementary material (Table S9 and Table S10)[89]. For RefSeq *bsh* sequences analysis, relative abundance was determined by normalizing to total abundance of *rplB* sequences also determined by Xander per sample. Significance was determined with Maaslin2 with same settings used for taxonomy analysis

Human metagenomic data from the European Bioinformatics Institute European Nucleotide Archive under accession number PRJEB6337 (<https://www.ebi.ac.uk/ena/data/view/PRJEB6337>) was analyzed using the same HUMAnN 3.0 pipeline as cecum metagenomic data. Fecal shotgun metagenomic samples from Chinese patients were defined as healthy (n=52) or cirrhotic with subclassifications of compensated (n=48) or decompensated (n=44) by the authors[40]. Cirrhosis was diagnosed by either biopsy, clinical evidence of decompensation or other metrics including radiological evidence of liver nodularity and intra-abdominal varices in a patient with chronic liver disease[40]. The subclassification was used as fixed effect for analysis with healthy as the reference category. Again, Maaslin2 was used with settings used for functional analysis with diagnosis as a fixed effect with healthy diagnosis as reference to determine adjusted *p*-values for compensated and decompensated patient designations.

Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Stacked bar plots of annotated EC number mean relative abundance and classified species involved in isoprenoid biosynthesis in cecum of TCDD-exposed mice, Figure S2: Stacked bar plots of mean relative abundance of annotated EC numbers and classified to *Lactobacillus* species involved in isoprenoid biosynthesis in cecums of TCDD-exposed mice, Figure S3: Stacked bar plots of annotated EC number mean relative abundance classified to respective species and involved in mevalonate dependent isoprenoid biosynthesis in cirrhotic patients, Table S1: Relative abundance of significantly changed *bsh* sequences in mouse cecums, Table S2: Significant Uniref90 annotations in murine cecum metagenomic dataset, Table S3: Enzyme commission numbers (EC) that were significant and annotated to at least *L. reuteri* in cecums of TCDD-exposed mice, Table S4: Enzyme commission numbers (EC) with species annotated to mevalonate-dependent IPP pathway for cirrhotic patients, Table S5: Total number of unique EC numbers determined to have greater than zero relative abundance in respective pathway (mevalonate and MEP isoprenoid biosynthesis, and menaquinone biosynthesis) in human cirrhosis patients, Table S6: Total number of unique EC numbers determined to have greater than zero relative abundance in respective pathway (mevalonate and MEP isoprenoid biosynthesis, and menaquinone biosynthesis) in TCDD-exposed mice, Table S7: Mean relative abundance denoted in counts per million (CPM) of EC annotations that were classified to *L. reuteri* and associating with chorismate biosynthesis., Table S8: EC numbers with relative abundance of species to menaquinone biosynthesis pathway for cirrhotic patients, Table S9: Nucleotide sequences used as reference in Xander *bsh* analysis, Table S10. Protein sequences used as reference in Xander *bsh* analysis.

Author Contributions: Conceptualization, R.F. and T.Z.; methodology, R.F. T.Z.; writing—original draft preparation, R.F.; writing—review and editing, R.F. T.Z.; funding acquisition, T.Z; formal analysis, R.F.; visualization, R.F.; data curation, R.F; Methodology R.F, T.Z; validation, R.F.; project administration, T.Z; investigation, R.F., T.Z; All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by the NIEHS Superfund Research Program (NIEHS SRP P42ES004911), and NIEHS R01ES029541 to T.Z. T.Z. is partially supported by AgBioResearch at Michigan State University. R.F. is supported by the NIEHS Multidisciplinary Training in Environmental Toxicology (NIEHS EHS T32ES007255).

Institutional Review Board Statement: All animal handling procedures were performed with the approval of the Michigan State University (MSU) Institutional Animal Care and Use Committee, in accordance with ethical guidelines and regulations under IACUC ID: PROTO201800043.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the human metagenomics study[40].

Data Availability Statement: Quality filtered mouse metagenomic data from this study can be found at the Sequence Read Archive (SRA) (<https://www.ncbi.nlm.nih.gov/sra>) under the accession

ID PRJNA719224. The human fecal metagenomic data presented in this study is openly available and can be found at the SRA under the accession number PRJEB6337[40].

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Younossi, Z.M.; Koenig, A.B.; Abdelatif, D.; Fazel, Y.; Henry, L.; Wymer, M. Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. *Hepatology* 2016, 64, 73–84, doi:10.1002/hep.28431.
2. Anstee, Q.M.; Targher, G.; Day, C.P. Progression of NAFLD to Diabetes Mellitus, Cardiovascular Disease or Cirrhosis. *Nat Rev Gastroenterol Hepatol* 2013, 10, 330–344, doi:10.1038/nrgastro.2013.41.
3. Tilg, H.; Moschen, A.R. Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis. *Hepatology* 2010, 52, 1836–1846, doi:10.1002/hep.24001.
4. Cave, M.; Appana, S.; Patel, M.; Falkner, K.C.; McClain, C.J.; Brock, G. Polychlorinated Biphenyls, Lead, and Mercury Are Associated with Liver Disease in American Adults: NHANES 2003-2004. *Environmental Health Perspectives* 2010, 118, 1735–1742, doi:10.1289/ehp.1002720.
5. Zheng, S.; Yang, Y.; Wen, C.; Liu, W.; Cao, L.; Feng, X.; Chen, J.; Wang, H.; Tang, Y.; Tian, L.; et al. Effects of Environmental Contaminants in Water Resources on Nonalcoholic Fatty Liver Disease. *Environment International* 2021, 154, 106555, doi:10.1016/j.envint.2021.106555.
6. Kumar, J.; Lind, L.; Salihovic, S.; van Bavel, B.; Ingelsson, E.; Lind, P.M. Persistent Organic Pollutants and Liver Dysfunction Biomarkers in a Population-Based Human Sample of Men and Women. *Environmental Research* 2014, 134, 251–256, doi:10.1016/j.envres.2014.07.023.
7. Rantakokko, P.; Männistö, V.; Airaksinen, R.; Koponen, J.; Viluksela, M.; Kiviranta, H.; Pihlajamäki, J. Persistent Organic Pollutants and Non-Alcoholic Fatty Liver Disease in Morbidly Obese Patients: A Cohort Study. *Environmental Health* 2015, 14, 79, doi:10.1186/s12940-015-0066-z.
8. Zhang, L.; Nichols, R.G.; Correll, J.; Murray, I.A.; Tanaka, N.; Smith, P.B.; Hubbard, T.D.; Sebastian, A.; Albert, I.; Hatzakis, E.; et al. Persistent Organic Pollutants Modify Gut Microbiota–Host Metabolic Homeostasis in Mice through Aryl Hydrocarbon Receptor Activation. *Environmental Health Perspectives* 2015, 123, 679–88, doi:10.1289/ehp.1409055.
9. Fader, K.A.; Nault, R.; Zhang, C.; Kumagai, K.; Harkema, J.R.; Zacharewski, T.R. 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD)-Elicited Effects on Bile Acid Homeostasis: Alterations in Biosynthesis, Enterohepatic Circulation, and Microbial Metabolism. *Scientific Reports* 2017, 7, 5921, doi:10.1038/s41598-017-05656-8.
10. Petriello, M.C.; Hoffman, J.B.; Vsevolozhskaya, O.; Morris, A.J.; Hennig, B. Dioxin-like PCB 126 Increases Intestinal Inflammation and Disrupts Gut Microbiota and Metabolic Homeostasis. *Environmental Pollution* 2018, 242, 1022–1032, doi:10.1016/j.envpol.2018.07.039.
11. Stedtfeld, R.D.; Chai, B.; Crawford, R.B.; Stedtfeld, T.M.; Williams, M.R.; Xiangwen, S.; Kuwahara, T.; Cole, J.R.; Kaminski, N.E.; Tiedje, J.M.; et al. Modulatory Influence of Segmented Filamentous Bacteria on Transcriptomic Response of Gnotobiotic Mice Exposed to TCDD. *Frontiers in microbiology* 2017, 8, 1708, doi:10.3389/fmicb.2017.01708.
12. Nault, R.; Fader, K.A.; Lydic, T.A.; Zacharewski, T.R. Lipidomic Evaluation of Aryl Hydrocarbon Receptor-Mediated Hepatic Steatosis in Male and Female Mice Elicited by 2,3,7,8-Tetrachlorodibenzo-p-dioxin., doi:10.1021/acs.chemrestox.6b00430.
13. Nault, R.; Fader, K.A.; Ammendolia, D.A.; Dornbos, P.; Potter, D.; Sharratt, B.; Kumagai, K.; Harkema, J.R.; Lunt, S.Y.; Matthews, J.; et al. Dose-Dependent Metabolic Reprogramming and Differential Gene Expression in TCDD-Elicited Hepatic Fibrosis. *Toxicological Sciences* 2016, 154, 253–266, doi:10.1093/toxsci/kfw163.
14. Fader, K.A.; Nault, R.; Ammendolia, D.A.; Harkema, J.R.; Williams, K.J.; Crawford, R.B.; Kaminski, N.E.; Potter, D.; Sharratt, B.; Zacharewski, T.R. 2,3,7,8-Tetrachlorodibenzo-p-Dioxin Alters Lipid Metabolism and Depletes Immune Cell Populations in the Jejunum of C57BL/6 Mice. *Toxicological Sciences* 2015, 148, 567–580, doi:10.1093/toxsci/kfv206.

15. Nault, R.; Fader, K.A.; Lydic, T.A.; Zacharewski, T.R. Lipidomic Evaluation of Aryl Hydrocarbon Receptor-Mediated Hepatic Steatosis in Male and Female Mice Elicited by 2,3,7,8-Tetrachlorodibenzo-p-dioxin., doi:10.1021/acs.chemrestox.6b00430.
16. Angrish, M.M.; Dominici, C.Y.; Zacharewski, T.R. TCDD-Elicited Effects on Liver, Serum, and Adipose Lipid Composition in C57BL/6 Mice. *Toxicological Sciences* 2013, 131, 108–115, doi:10.1093/toxsci/kfs277.
17. Katsiki, N.; Mikhailidis, D.P.; Mantzoros, C.S. Non-Alcoholic Fatty Liver Disease and Dyslipidemia: An Update. *Metabolism* 2016, 65, 1109–1123, doi:10.1016/j.metabol.2016.05.003.
18. Cholic, G.N.; Fling, R.R.; Zacharewski, N.A.; Fader, K.A.; Nault, R.; Zacharewski, T. Thioesterase Induction by 2,3,7,8-Tetrachlorodibenzo-p-Dioxin Results in a Futile Cycle That Inhibits Hepatic β -Oxidation; *Pharmacology and Toxicology*, 2021;
19. Fernandez-Salguero, P.M.; Hillbert, D.M.; Rudikoff, S.; Ward, J.M.; Gonzalez, F.J. Aryl-Hydrocarbon Receptor-Deficient Mice Are Resistant to 2,3,7,8-Tetrachlorodibenzo-p-Dioxin-Induced Toxicity. *Toxicology and Applied Pharmacology* 1996, 140, 173–179, doi:10.1006/taap.1996.0210.
20. Bock, K.W. Aryl Hydrocarbon Receptor (AHR)-Mediated Inflammation and Resolution: Non-Genomic and Genomic Signaling. *Biochemical Pharmacology* 2020, 182, 114220, doi:10.1016/j.bcp.2020.114220.
21. Schiering, C.; Wincent, E.; Metidji, A.; Iseppon, A.; Li, Y.; Potocnik, A.J.; Omenetti, S.; Henderson, C.J.; Wolf, C.R.; Nebert, D.W.; et al. Feedback Control of AHR Signalling Regulates Intestinal Immunity. *Nature* 2017, 542, 242–245, doi:10.1038/nature21080.
22. Grabherr, F.; Grander, C.; Effenberger, M.; Adolph, T.E.; Tilg, H. Gut Dysfunction and Non-Alcoholic Fatty Liver Disease. *Front. Endocrinol.* 2019, 10, 611, doi:10.3389/fendo.2019.00611.
23. Leung, C.; Rivera, L.; Furness, J.B.; Angus, P.W. The Role of the Gut Microbiota in NAFLD. *Nature Reviews Gastroenterology and Hepatology* 2016, 13, 412–425, doi:10.1038/nrgastro.2016.85.
24. Tian, J.; Feng, Y.; Fu, H.; Xie, H.Q.; Jiang, J.X.; Zhao, B. The Aryl Hydrocarbon Receptor: A Key Bridging Molecule of External and Internal Chemical Signals. *Environmental science & technology* 2015, 49, 9518–31, doi:10.1021/acs.est.5b00385.
25. Rothhammer, V.; Quintana, F.J. The Aryl Hydrocarbon Receptor: An Environmental Sensor Integrating Immune Responses in Health and Disease. *Nat Rev Immunol* 2019, 19, 184–197, doi:10.1038/s41577-019-0125-8.
26. Qiu, J.; Heller, J.J.; Guo, X.; Chen, Z.M.E.; Fish, K.; Fu, Y.X.; Zhou, L. The Aryl Hydrocarbon Receptor Regulates Gut Immunity through Modulation of Innate Lymphoid Cells. *Immunity* 2012, 36, 92–104, doi:10.1016/j.immuni.2011.11.011.
27. Zelante, T.; Iannitti, R.G.; Cunha, C.; DeLuca, A.; Giovannini, G.; Pieraccini, G.; Zecchi, R.; D'Angelo, C.; Massi-Benedetti, C.; Fallarino, F.; et al. Tryptophan Catabolites from Microbiota Engage Aryl Hydrocarbon Receptor and Balance Mucosal Reactivity via Interleukin-22. *Immunity* 2013, 39, 372–385, doi:10.1016/j.immuni.2013.08.003.
28. Murray, I.A.; Nichols, R.G.; Zhang, L.; Patterson, A.D.; Perdew, G.H. Expression of the Aryl Hydrocarbon Receptor Contributes to the Establishment of Intestinal Microbial Community Structure in Mice. *Scientific Reports* 2016, 6, 33969, doi:10.1038/srep33969.
29. Lefever, D.E.; Xu, J.; Chen, Y.; Huang, G.; Tamas, N.; Guo, T.L. TCDD Modulation of Gut Microbiome Correlated with Liver and Immune Toxicity in Streptozotocin (STZ)-Induced Hyperglycemic Mice. *Toxicology and Applied Pharmacology* 2016, 304, 48–58, doi:10.1016/j.taap.2016.05.016.
30. Neamah, W.H.; Busbee, P.B.; Alghetaa, H.; Abdulla, O.A.; Nagarkatti, M.; Nagarkatti, P. AhR Activation Leads to Alterations in the Gut Microbiome with Consequent Effect on Induction of Myeloid Derived Suppressor Cells in a CXCR2-Dependent Manner. *Int. J. Mol. Sci.* 2020, 18.
31. Stedtfeld, R.D.; Brett Sallach, J.; Crawford, R.B.; Stedtfeld, T.M.; Williams, M.R.; Waseem, H.; Johnston, C.T.; Li, H.; Teppen, B.J.; Kaminski, N.E.; et al. TCDD Administered on Activated Carbon Eliminates Bioavailability and Subsequent Shifts to a Key Murine Gut Commensal. *Applied Microbiology and Biotechnology* 2017, 101, 7409–7415, doi:10.1007/s00253-017-8460-9.
32. Shao, J.-W.; Ge, T.-T.; Chen, S.-Z.; Wang, G.; Yang, Q.; Huang, C.-H.; Xu, L.-C.; Chen, Z. Role of Bile Acids in Liver Diseases Mediated by the Gut Microbiome. *WJG* 2021, 27, 3010–3021, doi:10.3748/wjg.v27.i22.3010.
33. Marion, S.; Desharnais, L.; Studer, N.; Dong, Y.; Notter, M.D.; Poudel, S.; Menin, L.; Janowczyk, A.; Hettich, R.L.; Hapfelmeier, S.; et al. Biogeography of Microbial Bile Acid Transformations along the Murine Gut. *Journal of Lipid Research* 2020, 61, 1450–1463, doi:10.1194/jlr.RA120001021.

34. Foley, M.H.; O'Flaherty, S.; Allen, G.; Rivera, A.J.; Stewart, A.K.; Barrangou, R.; Theriot, C.M. Lactobacillus Bile Salt Hydrolase Substrate Specificity Governs Bacterial Fitness and Host Colonization. *Proc Natl Acad Sci USA* 2021, 118, e2017709118, doi:10.1073/pnas.2017709118.
35. Matsubara, T.; Li, F.; Gonzalez, F.J. FXR Signaling in the Enterohepatic System. *Molecular and Cellular Endocrinology* 2013, 368, 17–29, doi:10.1016/j.mce.2012.05.004.
36. Shapiro, H.; Kolodziejczyk, A.A.; Halstuch, D.; Elinav, E. Bile Acids in Glucose Metabolism in Health and Disease. *Journal of Experimental Medicine* 2018, 215, 383–396, doi:10.1084/jem.20171965.
37. Pols, T.W.H.; Noriega, L.G.; Nomura, M.; Auwerx, J.; Schoonjans, K. The Bile Acid Membrane Receptor TGR5: A Valuable Metabolic Target. *Dig Dis* 2011, 29, 37–44, doi:10.1159/000324126.
38. Fiorucci, S.; Mencarelli, A.; Palladino, G.; Cipriani, S. Bile-Acid-Activated Receptors: Targeting TGR5 and Farnesoid-X-Receptor in Lipid and Glucose Disorders. *Trends in Pharmacological Sciences* 2009, 30, 570–580, doi:10.1016/j.tips.2009.08.001.
39. O'Flaherty, S.; Briner Crawley, A.; Theriot, C.M.; Barrangou, R. The Lactobacillus Bile Salt Hydrolase Repertoire Reveals Niche-Specific Adaptation. *mSphere* 2018, 3, e00140-18, /msphere/3/3/mSphere140-18.atom, doi:10.1128/mSphere.00140-18.
40. Shao, L.; Ling, Z.; Chen, D.; Liu, Y.; Yang, F.; Li, L. Disorganized Gut Microbiome Contributed to Liver Cirrhosis Progression: A Meta-Omics-Based Study. *Front. Microbiol.* 2018, 9, 3166, doi:10.3389/fmicb.2018.03166.
41. Fazili, T.; Riddell, S.; Kiska, D.; Endy, T.; Giurgea, L.; Sharngoe, C.; Javaid, W. Streptococcus Anginosus Group Bacterial Infections. *The American Journal of the Medical Sciences* 2017, 354, 257–261, doi:10.1016/j.amjms.2017.05.011.
42. Workman, S.D.; Strynadka, N.C.J. A Slippery Scaffold: Synthesis and Recycling of the Bacterial Cell Wall Carrier Lipid. *Journal of Molecular Biology* 2020, 432, 4964–4982, doi:10.1016/j.jmb.2020.03.025.
43. Johnston, J.M.; Bulloch, E.M. Advances in Menaquinone Biosynthesis: Sublocalisation and Allosteric Regulation. *Current Opinion in Structural Biology* 2020, 65, 33–41, doi:10.1016/j.sbi.2020.05.005.
44. Hernández, S.B.; Cava, F.; Pucciarelli, M.G.; García-del Portillo, F.; de Pedro, M.A.; Casadesús, J. Bile-Induced Peptidoglycan Remodelling in *S. Almonella Enterica*: Bile-Induced Peptidoglycan Remodelling. *Environ Microbiol* 2015, 17, 1081–1089, doi:10.1111/1462-2920.12491.
45. Ravcheev, D.A.; Thiele, I. Genomic Analysis of the Human Gut Microbiome Suggests Novel Enzymes Involved in Quinone Biosynthesis. *Front. Microbiol.* 2016, 7, doi:10.3389/fmicb.2016.00128.
46. Aron-Wisnewsky, J.; Vigliotti, C.; Witjes, J.; Le, P.; Holleboom, A.G.; Verheij, J.; Nieuwdorp, M.; Clément, K. Gut Microbiota and Human NAFLD: Disentangling Microbial Signatures from Metabolic Disorders. *Nature Reviews Gastroenterology & Hepatology* 2020, 17, 279–297, doi:10.1038/s41575-020-0269-9.
47. Qiao, Y.; Sun, J.; Xia, S.; Li, L.; Li, Y.; Wang, P.; Shi, Y.; Le, G. Effects of Different Lactobacillus Reuteri on Inflammatory and Fat Storage in High-Fat Diet-Induced Obesity Mice Model. *Journal of Functional Foods* 2015, 14, 424–434, doi:10.1016/j.jff.2015.02.013.
48. Ting, W.-J.; Kuo, W.-W.; Hsieh, D.; Yeh, Y.-L.; Day, C.-H.; Chen, Y.-H.; Chen, R.-J.; Padma, V.; Chen, Y.-H.; Huang, C.-Y. Heat Killed Lactobacillus Reuteri GMNL-263 Reduces Fibrosis Effects on the Liver and Heart in High Fat Diet-Hamsters via TGF- β Suppression. *IJMS* 2015, 16, 25881–25896, doi:10.3390/ijms161025881.
49. Andreasen, A.S.; Larsen, N.; Pedersen-Skovsgaard, T.; Berg, R.M.G.; Møller, K.; Svendsen, K.D.; Jakobsen, M.; Pedersen, B.K. Effects of Lactobacillus Acidophilus NCFM on Insulin Sensitivity and the Systemic Inflammatory Response in Human Subjects. *Br J Nutr* 2010, 104, 1831–1838, doi:10.1017/S0007114510002874.
50. Khare, A.; Gaur, S. Cholesterol-Lowering Effects of Lactobacillus Species. *Curr Microbiol* 2020, 77, 638–644, doi:10.1007/s00284-020-01903-w.
51. Roh, Y.S.; Cho, A.; Cha, Y.-S.; Oh, S.-H.; Lim, C.W.; Kim, B. Lactobacillus Aggravate Bile Duct Ligation-Induced Liver Inflammation and Fibrosis in Mice. *ToxicolRes* 2018, 34, 241–247, doi:10.5487/TR.2018.34.3.241.
52. Martoni, C.J.; Labbé, A.; Ganopolsky, J.G.; Prakash, S.; Jones, M.L. Changes in Bile Acids, FGF-19 and Sterol Absorption in Response to Bile Salt Hydrolase Active L. Reuteri NCIMB 30242. *Gut Microbes* 2015, 6, 57–65, doi:10.1080/19490976.2015.1005474.
53. Kumar, R.; Grover, S.; Batish, V.K. Hypocholesterolaemic Effect of Dietary Inclusion of Two Putative Probiotic Bile Salt Hydrolase-Producing Lactobacillus Plantarum Strains in Sprague–Dawley Rats. *Br J Nutr* 2011, 105, 561–573, doi:10.1017/S0007114510003740.
54. Lee, N.Y.; Shin, M.J.; Youn, G.S.; Yoon, S.J.; Choi, Y.R.; Kim, H.S.; Gupta, H.; Han, S.H.; Kim, B.K.; Lee, D.Y.; et al. Lactobacillus Attenuates Progression of Nonalcoholic Fatty Liver Disease by Lowering Cholesterol and Steatosis. *Clin Mol Hepatol* 2021, 27, 110–124, doi:10.3350/cmh.2020.0125.

55. Kemis, J.H.; Linke, V.; Barrett, K.L.; Boehm, F.J.; Traeger, L.L.; Keller, M.P.; Rabaglia, M.E.; Schueler, K.L.; Stapleton, D.S.; Gatti, D.M.; et al. Genetic Determinants of Gut Microbiota Composition and Bile Acid Profiles in Mice. *PLoS Genet* 2019, 15, e1008073, doi:10.1371/journal.pgen.1008073.
56. Fung, T.C.; Vuong, H.E.; Luna, C.D.G.; Pronovost, G.N.; Aleksandrova, A.A.; Riley, N.G.; Vavilina, A.; McGinn, J.; Rendon, T.; Forrest, L.R.; et al. Intestinal Serotonin and Fluoxetine Exposure Modulate Bacterial Colonization in the Gut. *Nat Microbiol* 2019, 4, 2064–2073, doi:10.1038/s41564-019-0540-4.
57. Tannock, G.W.; Dashkevich, M.P.; Feighner, S.D. Lactobacilli and Bile Salt Hydrolase in the Murine Intestinal Tract. *Appl Environ Microbiol* 1989, 55, 1848–1851, doi:10.1128/aem.55.7.1848-1851.1989.
58. Winston, J.A.; Rivera, A.; Cai, J.; Patterson, A.D.; Theriot, C.M. Secondary Bile Acid Ursodeoxycholic Acid Alters Weight, the Gut Microbiota, and the Bile Acid Pool in Conventional Mice. *PLoS ONE* 2021, 16, e0246161, doi:10.1371/journal.pone.0246161.
59. Chae, J.P.; Valeriano, V.D.; Kim, G.-B.; Kang, D.-K. Molecular Cloning, Characterization and Comparison of Bile Salt Hydrolases from *Lactobacillus Johnsonii* PF01. *J Appl Microbiol* 2013, 114, 121–133, doi:10.1111/jam.12027.
60. Déjean, G.; Tudela, H.; Bruno, L.; Kissi, D.; Rawadi, G.; Claus, S.P. Identifying a Novel Bile Salt Hydrolase from the Keystone Gut Bacterium *Christensenella Minuta*. *Microorganisms* 2021, 9, 1252, doi:10.3390/microorganisms9061252.
61. De Smet, I.; Van Hoorde, L.; Vande Woestyne, M.; Christiaens, H.; Verstraete, W. Significance of Bile Salt Hydrolytic Activities of Lactobacilli. *Journal of Applied Bacteriology* 1995, 79, 292–301, doi:10.1111/j.1365-2672.1995.tb03140.x.
62. Bustos, A.Y.; Saavedra, L.; de Valdez, G.F.; Raya, R.R.; Taranto, M.P. Relationship between Bile Salt Hydrolase Activity, Changes in the Internal pH and Tolerance to Bile Acids in Lactic Acid Bacteria. *Biotechnol Lett* 2012, 34, 1511–1518, doi:10.1007/s10529-012-0932-5.
63. Sato, H.; Macchiarulo, A.; Thomas, C.; Gioiello, A.; Une, M.; Hofmann, A.F.; Saladin, R.; Schoonjans, K.; Pellicciari, R.; Auwerx, J. Novel Potent and Selective Bile Acid Derivatives as TGR5 Agonists: Biological Screening, Structure–Activity Relationships, and Molecular Modeling Studies. *J. Med. Chem.* 2008, 51, 1831–1841, doi:10.1021/jm7015864.
64. Wahlström, A.; Sayin, S.I.; Marschall, H.-U.; Bäckhed, F. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. *Cell Metabolism* 2016, 24, 41–50, doi:10.1016/j.cmet.2016.05.005.
65. Vranová, E.; Coman, D.; Gruissem, W. Network Analysis of the MVA and MEP Pathways for Isoprenoid Synthesis. *Annu. Rev. Plant Biol.* 2013, 64, 665–700, doi:10.1146/annurev-arplant-050312-120116.
66. Stacchiotti, V.; Rezzi, S.; Eggersdorfer, M.; Galli, F. Metabolic and Functional Interplay between Gut Microbiota and Fat-Soluble Vitamins. *Critical Reviews in Food Science and Nutrition* 2020, 1–22, doi:10.1080/10408398.2020.1793728.
67. Brooijmans, R.; Smit, B.; Santos, F.; van Riel, J.; de Vos, W.M.; Hugenholtz, J. Heme and Menaquinone Induced Electron Transport in Lactic Acid Bacteria. *Microb Cell Fact* 2009, 8, 28, doi:10.1186/1475-2859-8-28.
68. Ianniello, R.G.; Zheng, J.; Zotta, T.; Ricciardi, A.; Gänzle, M.G. Biochemical Analysis of Respiratory Metabolism in the Heterofermentative *Lactobacillus Spicheri* and *Lactobacillus Reuteri*. *J Appl Microbiol* 2015, 119, 763–775, doi:10.1111/jam.12853.
69. Plichta, D.R.; Somani, J.; Pichaud, M.; Wallace, Z.S.; Fernandes, A.D.; Perugino, C.A.; Lähdesmäki, H.; Stone, J.H.; Vlamakis, H.; Chung, D.C.; et al. Congruent Microbiome Signatures in Fibrosis-Prone Autoimmune Diseases: IgG4-Related Disease and Systemic Sclerosis. *Genome Med* 2021, 13, 35, doi:10.1186/s13073-021-00853-7.
70. Quinn, R.A.; Whiteson, K.; Lim, Y.W.; Zhao, J.; Conrad, D.; LiPuma, J.J.; Rohwer, F.; Widder, S. Ecological Networking of Cystic Fibrosis Lung Infections. *npj Biofilms Microbiomes* 2016, 2, 4, doi:10.1038/s41522-016-0002-1.
71. Chu, N.-N.; Chen, W.-L.; Xu, H.-R.; Li, X.-N. Pharmacokinetics and Safety of Ezetimibe/Simvastatin Combination Tablet: An Open-Label, Single-Dose Study in Healthy Chinese Subjects. *Clin Drug Investig* 2012, 32, 791–798, doi:10.1007/s40261-012-0013-5.
72. Ashrafizadeh, M.; Ahmadi, Z. Effects of Statins on Gut Microbiota (Microbiome). 6, 5.
73. Whitaker, E.; Alshammari, A. Bacteriostatic Effect of Simvastatin on Selected Oral Streptococci in Vitro. *Contemp Clin Dent* 2017, 8, 59, doi:10.4103/ccd.ccd_848_16.
74. Wu, S.; Jiang, P.; Zhao, X.-M.; Chen, W.-H. Treatment Regimens May Compromise Gut-Microbiome-Derived Signatures for Liver Cirrhosis. *Cell Metabolism* 2021, 33, 455–456, doi:10.1016/j.cmet.2021.02.012.
75. Loomba, R.; Seguritan, V.; Li, W.; Long, T.; Klitgord, N.; Bhatt, A.; Dulai, P.S.; Caussy, C.; Bettencourt, R.; Highlander, S.K.; et al. Gut Microbiome-Based Metagenomic Signature for Non-Invasive Detection of Advanced Fi-

- 777 brosis in Human Nonalcoholic Fatty Liver Disease. *Cell Metabolism* 2017, 25, 1054-1062.e5,
778 doi:10.1016/j.cmet.2017.04.001.
- 779 76. Thaïss, C.A.; Zeevi, D.; Levy, M.; Zilberman-Schapira, G.; Suez, J.; Tengeler, A.C.; Abramson, L.; Katz, M.N.;
780 Korem, T.; Zmora, N.; et al. Transkingdom Control of Microbiota Diurnal Oscillations Promotes Metabolic Ho-
781 meostasis. *Cell* 2014, 159, 514–529, doi:10.1016/j.cell.2014.09.048.
- 782 77. Fader, K.A.; Nault, R.; Doskey, C.M.; Fling, R.R.; Zacharewski, T.R. 2,3,7,8-Tetrachlorodibenzo-p-Dioxin Abol-
783 ishes Circadian Regulation of Hepatic Metabolic Activity in Mice. *Scientific Reports* 2019, 9, 1–18,
784 doi:10.1038/s41598-019-42760-3.
- 785 78. Plant, L.; Conway, P. Association of *Lactobacillus* Spp. with Peyer's Patches in Mice. *Clin Diagn Lab Immunol*
786 2001, 8, 320–324, doi:10.1128/CDLI.8.2.320-324.2001.
- 787 79. Wang, P.; Li, Y.; Xiao, H.; Shi, Y.; Le, G.; Sun, J. Isolation of *Lactobacillus Reuteri* from Peyer's Patches and Their
788 Effects on SIgA Production and Gut Microbiota Diversity. *Mol. Nutr. Food Res.* 2016, 60, 2020–2030,
789 doi:10.1002/mnfr.201501065.
- 790 80. Fader, K.A.; Nault, R.; Raehtz, S.; McCabe, L.R.; Zacharewski, T.R. 2,3,7,8-Tetrachlorodibenzo-p-Dioxin
791 Dose-Dependently Increases Bone Mass and Decreases Marrow Adiposity in Juvenile Mice. *Toxicology and*
792 *Applied Pharmacology* 2018, 348, 85–98, doi:10.1016/j.taap.2018.04.013.
- 793 81. Collins, F.L.; Irwin, R.; Bierhalter, H.; Schepper, J.; Britton, R.A.; Parameswaran, N.; McCabe, L.R. *Lactobacillus*
794 *Reuteri* 6475 Increases Bone Density in Intact Females Only under an Inflammatory Setting. *PLoS ONE* 2016, 11,
795 1–17, doi:10.1371/journal.pone.0153180.
- 796 82. Langmead, B.; Salzberg, S.L. Fast Gapped-Read Alignment with Bowtie 2. *Nat Methods* 2012, 9, 357–359,
797 doi:10.1038/nmeth.1923.
- 798 83. Danecek, P.; Bonfield, J.K.; Liddle, J.; Marshall, J.; Ohan, V.; Pollard, M.O.; Whitwham, A.; Keane, T.; McCarthy,
799 S.A.; Davies, R.M.; et al. Twelve Years of SAMtools and BCFtools. *GigaScience* 2021, 10, giab008,
800 doi:10.1093/gigascience/giab008.
- 801 84. Quinlan, A.R.; Hall, I.M. BEDTools: A Flexible Suite of Utilities for Comparing Genomic Features. *Bioinformatics*
802 2010, 26, 841–842, doi:10.1093/bioinformatics/btq033.
- 803 85. Mallick, H.; Rahnavard, A.; McIver, L.J.; Ma, S.; Zhang, Y.; Nguyen, L.H.; Tickle, T.L.; Weingart, G.; Ren, B.;
804 Schwager, E.H.; et al. Multivariable Association Discovery in Population-Scale Meta-Omics Studies; *Microbiol-*
805 *ogy*, 2021;
- 806 86. Love, M.I.; Huber, W.; Anders, S. Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data with
807 DESeq2. *Genome Biology* 2014, 15, 1–21, doi:10.1186/s13059-014-0550-8.
- 808 87. Franzosa, E.A.; Morgan, X.C.; Segata, N.; Waldron, L.; Reyes, J.; Earl, A.M.; Giannoukos, G.; Boylan, M.R.; Ciulla,
809 D.; Gevers, D.; et al. Relating the Metatranscriptome and Metagenome of the Human Gut. *Proceedings of the*
810 *National Academy of Sciences of the United States of America* 2014, 111, E2329-38, doi:10.1073/pnas.1319284111.
- 811 88. Wang, Q.; Fish, J.A.; Gilman, M.; Sun, Y.; Brown, C.T.; Tiedje, J.M.; Cole, J.R. Xander: Employing a Novel
812 Method for Efficient Gene-Targeted Metagenomic Assembly. *Microbiome* 2015, 1–13,
813 doi:10.1186/s40168-015-0093-6.
- 814 89. Fish, J.A.; Chai, B.; Wang, Q.; Sun, Y.; Brown, C.T.; Tiedje, J.M.; Cole, J.R. FunGene: The Functional Gene Pipeline
815 and Repository. *Frontiers in Microbiology* 2013, 4, 1–14, doi:10.3389/fmicb.2013.00291.